TNF inhibitors, also called TNF blockers, biologic therapies, or anti-TNF drugs are drugs that help stop inflammation. They are used to treat diseases like Rheumatoid Arthritis (RA), juvenile arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), and Crohn's disease.
The tumor necrosis factor inhibitor drugs market growth is driven by rising incidences of various inflammatory conditions such as Rheumatoid Arthritis (RA), psoriasis, ankylosing spondylitis, Ulcerative Colitis (UC), Crohn's disease, and others. For instance, according to centers for disease control and prevention (CDC), in 2015, an estimated 1.3% of US adults (3 million) reported being diagnosed with Inflammatory Bowel Disease (either Crohn’s disease or ulcerative colitis.
However, the high cost of the tumor necrosis factor inhibitors drugs, stringent regulatory framework and high-quality standards set by market leaders are some of the major factors hindering the growth of the market.
On the basis of product, the Tumor Necrosis Factor Inhibitor Drugs market is segmented Etanercept, Infliximab, Golimumab, Adalimumab, and Certolizumab.
On the basis of distribution channel, TNF inhibitor drugs market is segmented into hospital pharmacies, speciality pharmacies, and online pharmacies. Among these, hospital pharmacies accounted for the largest market share in 2018, majorly driven by the high patient turnover in hospitals.
On the basis of the National Inpatient Sample data, the hospitalization rate increased significantly during 2003 to 2013 from 44.2 to 59.7 per 100,000 population when it was listed as any secondary diagnosis. The mean hospitalization costs were $11,345 for Crohn’s disease and $13,412 for ulcerative colitis.
Geographically, the market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.
North America is dominating the Tumor Necrosis Factor (TNF) Inhibitor Drugs market in 2018 and estimated to hold the largest market size over the forecast period (2019-2026) owing to the rising incidence of inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC), crohn's disease, and others.
Some of the major players in the tumor necrosis factor inhibitor drugs market are: Amgen Inc, AbbVie Inc, Pfizer, Inc, Novartis International AG, Johnson & Johnson Services, Merck & co., and others.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
